Dialysis Procedures Alter Metabolic Conditions.

Area of Science:

• Nephrology
• Metabolic Biochemistry

Background:

• Progressive chronic kidney disease (CKD) leads to the accumulation of uremic toxins, disrupting metabolic systems.
• Uremic toxins impair metabolic pathways, including the breakdown of free fatty acids by lipoprotein lipase (LPL) and hepatic lipase (HL).

Purpose of the Study:

• To investigate the impact of hemodialysis (HD) on metabolic functions in CKD patients.
• To analyze how anticoagulation and dialysate composition during HD affect lipid and glucose metabolism.

Main Methods:

• The study focuses on the effects of heparin and low molecular weight heparin on LPL and HL activity during HD.
• It examines the consequences of glucose in dialysate on carbohydrate metabolism and Amadori product accumulation.

Main Results:

• Hemodialysis with heparin-based anticoagulation causes temporary loss and degradation of LPL and HL, impairing triglyceride breakdown for at least 8 hours.
• Dialysis can lead to amino acid loss and disturbed glucose metabolism, with glucose in dialysate potentially promoting carbohydrate oxidation and Amadori product formation.

Conclusions:

• Hemodialysis exacerbates metabolic dysregulation in CKD patients by affecting lipid and amino acid metabolism.
• Further research is needed on anticoagulation strategies, dialysate glucose levels, and amino acid supplementation to mitigate these adverse effects.